Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2023-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业独立董事候选人声明（二）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate of a company, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is a formal statement related to board membership candidacy, not a financial report, audit, or earnings release. It does not contain financial data or results, nor is it an announcement of voting results or a proxy solicitation. The content fits best under Board/Management Information (MANG) as it pertains to board member nomination and qualifications.
2023-04-25 Chinese
亚宝药业董事会审计委员会2022年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee 2022 Annual Performance Report" of 亚宝药业集团股份有限公司. It details the audit committee's activities, meetings, evaluations of external auditors, internal audit guidance, review of financial reports, internal control assessments, and overall evaluation for the year 2022. The content focuses on the audit committee's duties and their fulfillment rather than presenting the full audited financial statements or the full annual report. The document length is 3680 characters, which is relatively short and consistent with a committee report rather than a full annual report or audit report. It is not a certification or a brief announcement but a detailed committee report on audit-related activities. This fits best with the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports on audit activities, excluding full annual reports. Therefore, the classification is AR with high confidence.
2023-04-25 Chinese
亚宝药业2022年内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' for the year 2022. It includes detailed auditor responsibilities, company responsibilities, and an audit opinion on the effectiveness of internal control over financial reporting as of December 31, 2022. The document is issued by a certified public accounting firm and contains signatures and certifications typical of an audit report. It is not a full annual report but a standalone audit report focused on internal control over financial reporting. The length of the document (6780 characters) supports it being a full report rather than a brief announcement. Therefore, the document fits the category of Audit Report / Information (AR).
2023-04-25 Chinese
亚宝药业2022年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" which translates to "Audit Report" for the fiscal year 2022. It contains detailed audit opinions, basis for audit opinions, key audit matters, and extensive financial statements including balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The presence of detailed audit procedures and auditor's responsibilities confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR).
2023-04-25 Chinese
亚宝药业集团股份有限公司第八届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of 亚宝药业集团股份有限公司 regarding the approval of the 2022 annual report, 2022 annual supervisory board work report, 2022 financial final accounts report, 2022 profit distribution plan, 2022 internal control evaluation report, and the 2023 first quarter report. It also includes the nomination of candidates for the next supervisory board. The document is a formal announcement of decisions made in a supervisory board meeting, including approval of reports and proposals to be submitted to the annual shareholders meeting. It does not contain the full annual report or detailed financial statements itself but rather the supervisory board's resolutions and opinions on these reports. The document length is short (2022 characters) and it serves as an official announcement of meeting resolutions and supervisory board opinions. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than the full Annual Report (10-K) or Interim Report (IR).
2023-04-25 Chinese
亚宝药业2022年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, audit opinions, and compliance with internal control standards. The content is focused on internal control evaluation rather than full financial statements or annual performance. The document length is 4334 characters, which is relatively short but contains detailed internal control evaluation information. This type of report aligns with an Audit Report / Information (AR) category, as it is a standalone internal control evaluation report, not a full Annual Report (10-K) or an announcement of a report (RPA). Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.